Sweden's Acarix Q1 revenue rises 40% on US market expansion

Acarix AB

18/05/2026 07:09

Overview

Sweden cardiac diagnostics firm's Q1 revenue rose 40%, with 61% currency-adjusted growth

Operating costs fell 32% and net loss improved 38% yr/yr

Company achieved EU MDR certification for CADScor System

Outlook

Company expects Saudi partner to order SEK 9.8 mln of products within six months after approval

Acarix remains focused on increasing utilization across installed base and advancing U.S. reimbursement efforts

Result Drivers

U.S. MARKET EXPANSION - Co said accelerating commercial momentum and strong demand for CADScor System drove 63% revenue growth in U.S. market

OPERATING COST REDUCTION - Co reduced operating costs by 32%, contributing to improved net loss

EU MDR CERTIFICATION - Co achieved EU MDR certification for CADScor System, validating safety and quality

Company press release: ID:nMFN6MK80Y

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 2.42 mln
Q1 EPS
-SEK 0.01
Q1 Gross Margin
81%


Analyst Coverage

Wall Street's median 12-month price target for Acarix AB is SEK0.40, about 54.1% above its May 15 closing price of SEK0.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)